Compare AbCellera Biologics Inc (ABCL) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs VanEck Gold Miners ETF — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while VanEck Gold Miners ETF trades at $73.27. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | GDX | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | — |
52-Week High | $8.12 | $115.84 |
52-Week Low | $2.78 | $50.79 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
GDX trades at $78.74, up 0.4% with bearish technical signals from moving averages but neutral oscillators. The ETF faces mixed sentiment as gold miners navigate volatile commodity markets, though some analysts highlight attractive valuations and strong fundamentals. Recent additions like Aya Gold & Silver to the ETF portfolio signal ongoing portfolio optimization.
The outlook remains cautious with technical resistance at $80-$83, while fundamental support comes from record free cash flow yields and discounted multiples. Key risks include gold price volatility and energy cost pressures, but central bank demand and portfolio diversification benefits provide long-term tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
